Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics Platform
Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, announced that the U.S. Patent and Trade Office (USPTO) has granted their first patent, granting twenty years of exclusivity for a number of key features core to the company’s digital therapeutics platform, designed to help treat cardiometabolic diseases through the delivery of digital behavioral therapy as a PDT.
Latest Aithority Insights : TIFIN Announces Magnifi Mentor, The First Conversational AI-Powered Assistant Designed For Investing
“Our team has been on the cutting edge of using software to help individuals change the behaviors that are the underlying causes of cardiometabolic conditions like type 2 diabetes and fatty liver disease”
“Our team has been on the cutting edge of using software to help individuals change the behaviors that are the underlying causes of cardiometabolic conditions like type 2 diabetes and fatty liver disease,” said Kevin Appelbaum, CEO of Better Therapeutics. “This work has resulted in a number of new and distinct inventions, and we are proud that this ingenuity has now been officially recognized by the USPTO.”
Browse The Complete News About Aithority : Ping Identity Solutions Now Available on AWS Marketplace Through Carahsoft
The new patent, U.S. Patent No. 11,355,228 granted on June 7th, 2022, is titled “SYSTEM, METHODS, AND APPARATUSES FOR MANAGING DATA FOR ARTIFICIAL INTELLIGENCE SOFTWARE AND MOBILE APPLICATIONS IN DIGITAL HEALTH THERAPEUTICS,” and covers methods and apparatus for generating and monitoring a therapy regimen employing Better Therapeutics’ innovative machine learning techniques. Taken together with the 510 days of patent term adjustment provided by the U.S. Patent and Trademark Office, Better Therapeutics’ exclusivity will extend until at least September of 2039, absent any further patent extensions.
The mechanisms covered in the patent are core to Better Therapeutics’ digital platform and relate to the way in which it uses machine learning and artificial intelligence to personalize treatment for each patient in order to optimize adherence and outcomes. Better Therapeutics remains on track to file its de novo submission to FDA for its first product – BT-001, a treatment for type 2 diabetes – following the completion of its pivotal clinical trial this month.
Read More About Aithority News : authID.ai Achieves ISO Certification for Information Security Management Systems
[To share your insights with us, please write to firstname.lastname@example.org]